Mitogen-activated Protein Kinase/extracellular Signal-regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8
Overview
Affiliations
Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) induce apoptosis in many different cell types. Jurkat T cells die rapidly by apoptosis after treatment with either ligand. We have previously shown that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) can act as a negative regulator of apoptosis mediated by the Fas receptor. In this study we examined whether MAPK/ERK can also act as a negative regulator of apoptosis induced by TRAIL. Activated Jurkat T cells were efficiently protected from TRAIL-induced apoptosis. The protection was shown to be MAPK/ERK dependent and independent of protein synthesis. MAPK/ERK suppressed TRAIL-induced apoptosis upstream of the mitochondrial amplification loop because mitochondrial depolarization and release of cytochrome c were inhibited. Furthermore, caspase-8-mediated relocalization and activation of Bid, a proapoptotic member of the Bcl family, was also inhibited by the MAPK/ERK signaling. The protection occurred at the level of the apoptotic initiator caspase-8, as the cleavage of caspase-8 was inhibited but the assembly of the death-inducing signaling complex was unaffected. Both TRAIL and Fas ligand have been suggested to regulate the clonal size and persistence of different T cell populations. Our previous results indicate that MAPK/ERK protects recently activated T cells from Fas receptor-mediated apoptosis during the initial phase of an immune response before the activation-induced cell death takes place. The results of this study show clearly that MAPK/ERK also participates in the inhibition of TRAIL-induced apoptosis after T cell activation.
Kaur G, Bae E, Zhang Y, Ciacciofera N, Jung K, Barreda H J Extracell Vesicles. 2024; 13(8):e12497.
PMID: 39140452 PMC: 11322862. DOI: 10.1002/jev2.12497.
Zhang L, Zhang W, Li Z, Lin S, Zheng T, Hao B J Exp Clin Cancer Res. 2022; 41(1):227.
PMID: 35864520 PMC: 9306053. DOI: 10.1186/s13046-022-02439-6.
Kim S, Ko I, Jin J, Hwang L, Kim C, Kim S Biomed Res Int. 2020; 2020:2169083.
PMID: 32149087 PMC: 7056995. DOI: 10.1155/2020/2169083.
RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer.
Gabriela-Freitas M, Pinheiro J, Raquel-Cunha A, Cardoso-Carneiro D, Martinho O Biomolecules. 2019; 9(12).
PMID: 31766768 PMC: 6995551. DOI: 10.3390/biom9120769.
Aherne S, Smyth P, Freeley M, Smith L, Spillane C, OLeary J Int J Mol Med. 2016; 38(2):433-45.
PMID: 27353001 PMC: 4935456. DOI: 10.3892/ijmm.2016.2653.